

## PROVINCIAL FUNDING SUMMARY

Sorafenib (Nexavar) for Differentiated Thyroid Cancer

pERC Recommendation: Does not recommend  
For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: July 31, 2015

This information is current as of June 30, 2016.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Not funded		
AB	Under provincial consideration		
SK	Not funded		
MB	Not funded		
ON	Not funded		
NS	Not funded		
NB	Not funded		
NL	Not funded		
PEI	Not funded		

*Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.